ENCINITAS, CALIF., November 4, 2023 – Kiora Pharmaceuticals (NASDAQ: KPRX) today announced topline results of a Phase I/II clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class small molecule, has the potential to meaningfully improve vision ...

In early August 2023, Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced a sharpened clinical development focus on rare retinal diseases with large unmet needs, initially dedicating attention to inherited retinal diseases (IRDs). Kiora recently completed a Phase 1b study of ...

Kiora Pharmaceuticals (NASDAQ: KPRX) KIO-301 is lighting up the eyes of some patients with retinitis pigmentosa (RP) in a Phase 1 clinical study, so much so that “I was blind, and now I can see” is not hyperbole. Kiora is expected to provide an update on the ongoing study in t...